Congress funds push to diagnose bleeding disorders missed in millions of women

What it does

This bill directs the Department of Health and Human Services to review federal programs and research on bleeding disorders in women and girls, identify gaps in diagnosis and treatment access, and produce a public report within two years. It then authorizes up to $10 million per year (2027–2031) for a national education and awareness campaign targeting women, girls, and healthcare providers to improve early diagnosis and treatment of bleeding disorders, particularly in rural and underserved areas.

Why we flagged it

The bill is a straightforward public-health measure authorizing a federal review and awareness campaign for an underdiagnosed condition affecting millions of women. It contains no tax provisions, subsidies, or regulatory changes—only research coordination and public education.

What the text implies

• The bill's focus on women and girls with bleeding disorders may indirectly increase demand for hemophilia treatment centers and specialized hematology services, potentially benefiting healthcare providers and medical institutions offering such care.
• Improved diagnosis rates could increase identification of carriers for hemophilia A and B, expanding the population eligible for preventive or monitoring services.
• The campaign's emphasis on avoiding unnecessary hysterectomies aligns with broader reproductive autonomy and fertility-preservation goals, but implementation depends on provider education and clinical practice change.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill addresses a documented public-health gap: women experience 16+ year diagnostic delays for bleeding disorders, leading to preventable complications, unnecessary hysterectomies, and higher mortality. The review and awareness campaign are designed to improve diagnosis rates and access to specialized care, particularly for underserved populations, with no offsetting costs to citizens.

Who stands to gain

• hemophilia treatment centers (increased patient volume)
• healthcare providers specializing in hematology and women's health
• organizations awarded grants for the awareness campaign

Named in the bill

Department of Health and Human Services, Centers for Medicare & Medicaid Services, Health Resources and Services Administration, Centers for Disease Control and Prevention, National Institutes of Health, Department of Veterans Affairs, Defense Health Agency, Food and Drug Administration, hemophilia treatment centers, von Willebrand disease, hemophilia A and B

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• May 13, 2026 — Introduced · Congress.gov: “Introduced in House”
• May 13, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $5,693,000 in lobbying spend. A filing names 103 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

• American Medical Association — $5,643,000 on 2 filings
• National Bleeding Disorder Foundation (fka National Hemophilia Foundation) — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.